The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

BACKGROUND: Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer treatment. METHODS: We examined data from PubMed, W...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jingjie, Li, Shengnan, Yao, Qigu, Du, Nannan, Fu, Xiaojun, Lou, Yuanmei, Wang, Mengru, Mao, Feiyan, Mao, Danyi, Khadaroo, Parikshit Asutosh, Tang, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334852/
https://www.ncbi.nlm.nih.gov/pubmed/32620130
http://dx.doi.org/10.1186/s12957-020-01933-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334852/
https://www.ncbi.nlm.nih.gov/pubmed/32620130
http://dx.doi.org/10.1186/s12957-020-01933-5

Ejemplares similares